Ginkgo Bioworks Holdings Inc Class A (DNA)

10.22
NYSE
Prev Close 11.39
Day Low/High 9.73 / 11.41
52 Wk Low/High 8.90 / 15.86
Exchange NYSE
Shares Outstanding 1608.81B
Market Cap 18.32B
Div & Yield N.A. (N.A)

Today's markets provide an immense challenge to money managers, like myself, who actively sell short.   On one hand, shorting the Indices (as I have had unprofitably done in the past) exposes a short seller to the massive and unrelenting flows going...

I am bidding slightly under the market to cover some of the following shorts: , , and .

* My revised levels I don't want there to be any ambiguity about the size of my positions, or about my buy and short levels, as I strive for as much transparency as possible. This column is a continued commitment towards that sort of disclosure. "Wh...

I was asked about borrow rates on Rivian in the Comments Section.  I thought it would be interesting to make a list of stocks that I am short in which the borrow rate is over 1%:  * 127% * 66% * 25% * 11% * 9% * 5% * 2% * 1%

Let's review areas that are hot, those that are not, and how to position though January.

Ginkgo Bioworks bears were gripping about Scorpion Capital alleged "front running" their DNA short analysis by purchasing puts.  Well, put activity is now way down - Friday's expiration was quite active - and Cathie Wood of ARK  has reported that it...

I have been adding to my short all week. And, I have added to short today (at $100.03).

There was a lot of reaction to the Ginkgo Bioworks Holdings short report on Twitter Wednesday not too long after it was published.

In two or three months, you won't hear a word on this again much like we've seen on so many other names.

DNA

A new short - Ginkgo Bioworks Holdings  , see here. More to come.

The mixed action on Monday is not a negative -- and here's why SPACs are getting interesting again.

But aggressive action by retail traders is one reason that I'm not too worried about a substantial correction at this time.